Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciae650 | DOI Listing |
Publication Analysis
Top Keywords
rapid selection
4
selection hiv-2
4
hiv-2 capsid
4
capsid mutations
4
mutations salvage
4
salvage therapy
4
therapy lenacapavir-containing
4
lenacapavir-containing regimen
4
regimen lenacapavir
4
lenacapavir capsid
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!